Health · Pharma & Biotech · 3 hrs ago

FDA approves Roche breast cancer drug for patients with ESR1 mutation

FDA approves Roche breast cancer drug for patients with ESR1 mutation

The FDA approved Roche’s giredestrant for certain adults with advanced breast cancer.

The treatment is for cancer that is estrogen-receptor positive, HER2-negative and has an ESR1 mutation.

This mutation can signal that the cancer is becoming resistant to standard treatments.

The drug is taken by mouth and is used with everolimus after cancer returns or progresses during or after certain hormone treatments.

In the evERA trial, the combination significantly extended the time before cancer worsened among patients with the mutation.

The FDA also cleared a blood test to find ESR1 mutations and identify people who may receive the treatment.

2 sources

Related